Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.

You may also be interested in...



AstraZeneca And Ironwood Link Up To Bring Linaclotide To China

Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.

AstraZeneca And Ironwood Link Up To Bring Linaclotide To China

Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.

New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP

Bayer’s aflibercept, Leo’s ingenol mebutate, Almirall’s linaclotide and a proteolytic enzyme concentrate, Teva’s NexoBrid, were given positive opinions on their marketing by CHMP on Sept. 21, with Almirall taking a different approach to linaclotide’s development than that taken in the U.S.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel